In a systematic search for a substance with antifibrinolytic properties Okamoto and his group in Japan found that several mercapto-and aminocarbonic acids were active. Of these substances epsilon-aminocaproic acid (EACA) had the strongest antifibrinolytic effect.1 2 The Japanese workers described it as a plasmin inhibitor in vitro and useful in inhibiting proteolytic enzymes in vivo. They gave EACA in a dose of 10-20 g a day by mouth or intravenously to over 100 patients and observed no toxic effects. Their investigation did not include any metabolic studies. EACA has since been widely used and its mode of action and pharmacokinetics intensively studied.
In a continued search for more potent antifibrinolytic components p-aminomethyl cyclohexane ,arboxylic acid (AMCHA) was found to be more potent than EACA.3 This compound contains two stereoisomers. Independently Melander et al. 4 and Okamoto et al.5 found that only the trans-form was antifibrinolytically active. The antifibrinolytically active form was called tranexamic acid (AMCA). It is [6] [7] [8] [9] [10] times stronger than EACA and is now used more widely. Its pharmacokinetics have been the subject of several studies. This paper surveys the pharmacology and toxicology of EACA and AMCA.
Pharmacokinetics AMINOCAPROIC ACID (EACA)
The absorption, distribution, and excretion of EACA given intravenously and by mouth have been studied in man.6-8 High-voltage electrophoresis and plasma amino-acid chromatography with ion exchange resin loaded paper were used for assaying EACA in plasma, serum, urine, and tissues.7-9 The blood was assayed for fibrinolytic activity by measuring the plasma euglobulin clot lysis time and/or the activity of plasma and of resuspended euglobulin precipitate on unheated and heated fibrin plates. The urokinase activity of After 100 mg/kg bodyweight by mouth the peak plasma concentration of EACA was 30 mg/100 ml two to three hours after ingestion (Fig. 1) . At four hours it was 16 mg/100 ml compared with 3 9 mg/100 ml four hours after intravenous injection. After six hours the concentration was similar to that found after intravenous administration. Renal excretion differed from that found after intravenous injection (Fig. 2) . Only 10% of the dose had been excreted within one hour, and 25% within three hours. The 24-hour urinary recovery after the oral administration was 64%. initial loading dose of 10 g followed by a continuous intravenous infusion of 1 g/hour to keep a steady plasma concentration of about 13 mg/100 ml. With these doses it has also been possible to inhibit the fibrinolytic activity induced by infusion of streptokinase. A therapeutic concentration can also be maintained by giving 0-1 g/kg bodyweight every 4-6 hours. 6 12 To inhibit the urokinase activity in the urine EACA has to be present in the urine in a concentration of about 0.1 mol/l-that is, 10 times higher than that needed to inhibit systemic fibrinolysis in plasma. But since the drug is greatly concentrated during excretion, the urinary concentrations being 50 to 100 times those in plasma, effective concentrations of urinary EACA can be achieved by giving smaller doses, which have only a slight systemic effect. Thus a dose of 3 g EACA three times a day is sufficient to inhibit the local fibrinolytic activity in the urinary tract.'2 TRANEXAMIC ACID (AMCA)
Andersson et al.8 13 first studied the absorption, distribution, and excretion of AMCA given intravenously and by mouth in man. They measured the acid in serum with a biological method as well as with high-voltage paper electrophoresis. AMCA in urine was measured by high-voltage paper electrophoresis. After intravenous administration of 10 mg AMCA/kg bodyweight the serum concentration was 18, 10, and 5 Htg/ml after 1, 3, and 5 hours, respectively (Fig. 3) . The biological half life was calculated to be about 80 hours. About 300% was recovered in the urine during the first hour, 55 % during the first three hours, and about 90 % within 24 hours (Fig. 4) .
After AMCA 10 mg/kg bodyweight by mouth the maximum serum concentration was only about 2 ,tg/ml after three hours. After 100 mg/kg by mouth a plasma concentration of 40 ,ug/ml was reached within four hours (Fig. 3) . Thus AMCA is not absorbed from the gastrointestinal tract so effectively as EACA. About 40% of an oral dose of 10-15 mg/kg was recovered in the urine within 24 hours (Fig. 4) Vessman and Str6mberg18 have developed a rapid gas chromatographic method for measuring AMCA in small biological samples. The lower limit of detection is 40 pg/ml. They studied the plasma concentration of AMCA after giving 0 5 g and 2-0 g by mouth. Peak concentrations of about 5 and 15 ,ug/ml, respectively, were noted within 2-4 hours. After 12 hours the concentration was less than 1 ,ug/ml.
Like EACA, AMCA is widely distributed throughout the extracellular and intracellular compartments. AMCA 1 g given 4-hourly intravenously to patients with subarachnoid haemorrhage enters the cerebrospinal fluid at a concentration of about [2] [3] [4] [5] jug/ml.19 Ahlberg et al.20 gave 10 mg AMCA/kg bodyweight to patients before knee joint operations. They found that AMCA rapidly diffused into the joint fluid and synovial membranes and reached the same concentration in the joint fluid as in the serum. The biological half life in the joint fluid was about 3 hours. Bramsen2' has investigated the aqueous humour concentration of AMCA after oral administration of the drug. On a dose of 25 mg AMCA/kg bodyweight three times a day the concentration within three hours was 1-6 ,ug/ml compared with a serum concentration of 15 ,tg/ml. The AMCA disappeared slowly from the aqueous humour.
Given by mouth or intravenously AMCA diffuses into semen and inhibits its normally high fibrinolytic activity. AMCA has no effect on the motility of spermatozoa.22 AMCA passes transplacentally to the fetus.23 After intravenous injection of 10 mg/kg bodyweight the concentration in the fetal serum may be anything between 4 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] hours before the operation in four doses of about [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] mg/kg bodyweight each. The corresponding dose of EACA was 100 mg/kg. The last dose was given at various intervals before operation. The results showed that the antifibrinolytically active concentration of AMCA (10 ,tg/ml) persisted longer in the tissues examined than did the corresponding concentration of EACA (100 ,ug/ml). AMCA thus has not only a higher fibrinolytic activity than EACA but it also persists longer in the tissues. After repeated intravenous or oral doses of AMCA (10 mg/kg intravenously 4-5 times a day or 20 mg/kg by mouth 3-4 times a day) an adequate antifibrinolytic activity in tissues can be maintained for up to 17 hours without any further dose. Risberg26 found a retention of AMCA in the lung tissue in rats.
Judging from in-vitro experiments and clinical experience control of systemic fibrinolysis requires a plasma AMCA concentration of about [10] [11] [12] [13] [14] [15] ,ug/ml. Since the drug is rapidly excreted in the urine it must, like EACA, be given intravenously at short intervals to maintain a therapeutic level. Andersson et al.8 13 recommended a dose of 10 mg/kg bodyweight every 3-4 hours. AMCA is not so readily absorbed as EACA and therefore when given by mouth is only three times as active as EACA. An oral dose of about 30-40 mg/kg bodyweight every 4-5 hours should be optimal in treating conditions with generalised fibrinolysis. For inhibiting tissue activators-that is, in the treatment of conditions associated with local fibrinolysis-AMCA has been recommended in a dose of about 20 mg/kg 3-4 times a day.
Inhibition of urokinase activity in the urine requires an AMCA concentration of about 200 ,ug/ml. After AMCA by mouth in a dose of 10 mg/kg bodyweight the fibrinolytic activity of the urine is much reduced (Fig. 6) . A dose of 1-2 g two to three times a day is sufficient to inhibit the urokinase activity in the urine. 
Toxicology
Both EACA and AMCA are of low acute toxicity.4 No fetal abnormalities have been found in teratogenic studies in rats, rabbits, and mice given AMCA in doses of up to 5000 ,ug/kg a day. Retinal changes have been reported in dogs after receiving AMCA by mouth over a period of one year in doses approximately seven times higher than the maximum recommended daily dose for man. No such changes were seen in dogs given for a year three and a half times the maximal oral dose per kg bodyweight recommended for man, in rats given seven times the maximal human dose for 22 months, or monkeys that had been given 18 times the maximal intravenous dose for 14 days.28 Neither were any retinal changes seen in patients treated with AMCA for months or years (Pandolfi, personal communication). In patients to be treated continuously for several weeks, however, visual acuity, colour perception, the ocular fundi, and fields of vision should be reviewed. Adenoma 
